Karl Tamussino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karl Tamussino has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
Vesna Bjelic-Radisic
Division of Gynecology, Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
5 shared publications- Edgar Petru
Department of Obstetrics and Gynecology, Division of Gynecology, Medical University of Graz, Graz, Austria
3 shared publications G. Tomasch
3 shared publicationsRene Laky
Department of Obstetrics & Gynecology, Medical University of Graz, Graz, Austria
3 shared publications- Selman Uranues
Section for Surgical Research, Department of Surgery, Medical University of Graz, Graz, Austria
3 shared publications Thomas Aigmüller
Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
3 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 339
High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage
High grade serous ovarian cancer (HGSC) has low survival partly due to the lack of methods for detection, diagnosis, and risk prediction. TP53 mutations, which drive HGSC, are found in gynecological tissues as the result of somatic evolution, but it is unknown whether an excess of mutations is linked to ovarian cancer. Here we investigate if TP53 mutation burden measured in uterine lavage, a minimally invasive gynecological liquid biopsy, can discriminate between patients with and without HGSC. We used ultradeep TP53 duplex sequencing (>15,000x duplex depth) to detect TP53 mutations in uterine lavage collected pre-operatively in 278 patients undergoing gynecological surgery for pelvic masses (average risk) or cancer risk-reduction (high risk). All lavages contained multiple TP53 mutant clones, which were used to quantify TP53 mutation burden frequency (MBF). Average risk patients with HGSC had significantly higher TP53 MBF independently of age and other risk factors (77% sensitivity, 89% specificity, AUC = 0.88). Excluding tumor TP53 clonal mutations from the lavage MBF calculation maintains this association, suggesting that it is the overall TP53 somatic mutation burden (rather than the discovery of the specific tumor driver mutation) that identifies HGSC. These results demonstrate that TP53 somatic mutations are common in uterine lavage but more abundant in patients with HGSC, highlighting a connection between TP53 somatic evolution and ovarian cancer. Uterine lavage offers a minimally invasive approach that could be valuable to identify patients with HGSC.
- 29 August 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 339
Open AccessHigh-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage
High grade serous ovarian cancer (HGSC) has low survival partly due to the lack of methods for detection, diagnosis, and risk prediction. TP53 mutations, which drive HGSC, are found in gynecological tissues as the result of somatic evolution, but it is unknown whether an excess of mutations is linked to ovarian cancer. Here we investigate if TP53 mutation burden measured in uterine lavage, a minimally invasive gynecological liquid biopsy, can discriminate between patients with and without HGSC. We used ultradeep TP53 duplex sequencing (>15,000x duplex depth) to detect TP53 mutations in uterine lavage collected pre-operatively in 278 patients undergoing gynecological surgery for pelvic masses (average risk) or cancer risk-reduction (high risk). All lavages contained multiple TP53 mutant clones, which were used to quantify TP53 mutation burden frequency (MBF). Average risk patients with HGSC had significantly higher TP53 MBF independently of age and other risk factors (77% sensitivity, 89% specificity, AUC = 0.88). Excluding tumor TP53 clonal mutations from the lavage MBF calculation maintains this association, suggesting that it is the overall TP53 somatic mutation burden (rather than the discovery of the specific tumor driver mutation) that identifies HGSC. These results demonstrate that TP53 somatic mutations are common in uterine lavage but more abundant in patients with HGSC, highlighting a connection between TP53 somatic evolution and ovarian cancer. Uterine lavage offers a minimally invasive approach that could be valuable to identify patients with HGSC.
- Open Access
- 18 July 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (3) , 796-807
Beyond procedure-specific protocols: a systematic review identifying a universal anaesthesiological core across Enhanced Recovery After Surgery Society guidelines
- 18 July 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (3) , 796-807
Open AccessBeyond procedure-specific protocols: a systematic review identifying a universal anaesthesiological core across Enhanced Recovery After Surgery Society guidelines
- Open Access
Spatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer
The intensification of neoadjuvant therapy for early triple-negative breast cancer (eTNBC) – through the addition of carboplatin to standard chemotherapy and the incorporation of pembrolizumab – has markedly improved prognosis in recent years. However, this escalation carries a substantial risk of toxicity, and not all patients require the full regimen to achieve benefit. Realizing individualized treatment strategies will therefore depend on prognostic and predictive biomarkers that can forecast treatment response and long-term outcome. In the present study, we interrogated public gene expression datasets to develop transcriptomic signatures predicting response to neoadjuvant treatment and risk of recurrence. To validate these signatures, we used the Multiplex8+ platform for spatially informed comprehensive transcriptomic profiling in a real-world, multicenter, retrospective cohort of 590 patients diagnosed with eTNBC and treated with neoadjuvant chemotherapy with or without immunotherapy. The diagnostic Multiplex8+ test uses H&E and multiplexed RNA-FISH to guide the selection of specific tumor areas for the whole transcriptome sequencing and signature analysis. In the real-world cohort, the Multiplex8+ signatures were associated with both response and prognosis, remaining highly significant in multivariable models that included clinical parameters. The signatures were complementary to established biomarkers such as stromal tumor-infiltrating lymphocytes. These findings warrant prospective integration of the signatures into risk-stratified clinical trials to support future de-escalation and escalation strategies, enabling a better balance of efficacy, toxicity, cost, and drug availability.
Open AccessSpatially informed comprehensive tumor transcriptomic profiling stratifies clinical outcomes in early triple negative breast cancer
The intensification of neoadjuvant therapy for early triple-negative breast cancer (eTNBC) – through the addition of carboplatin to standard chemotherapy and the incorporation of pembrolizumab – has markedly improved prognosis in recent years. However, this escalation carries a substantial risk of toxicity, and not all patients require the full regimen to achieve benefit. Realizing individualized treatment strategies will therefore depend on prognostic and predictive biomarkers that can forecast treatment response and long-term outcome. In the present study, we interrogated public gene expression datasets to develop transcriptomic signatures predicting response to neoadjuvant treatment and risk of recurrence. To validate these signatures, we used the Multiplex8+ platform for spatially informed comprehensive transcriptomic profiling in a real-world, multicenter, retrospective cohort of 590 patients diagnosed with eTNBC and treated with neoadjuvant chemotherapy with or without immunotherapy. The diagnostic Multiplex8+ test uses H&E and multiplexed RNA-FISH to guide the selection of specific tumor areas for the whole transcriptome sequencing and signature analysis. In the real-world cohort, the Multiplex8+ signatures were associated with both response and prognosis, remaining highly significant in multivariable models that included clinical parameters. The signatures were complementary to established biomarkers such as stromal tumor-infiltrating lymphocytes. These findings warrant prospective integration of the signatures into risk-stratified clinical trials to support future de-escalation and escalation strategies, enabling a better balance of efficacy, toxicity, cost, and drug availability.
- Top Cited PapersOpen Access
- 10 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (2) , 167-179
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
PURPOSE: Simple hysterectomy and pelvic node assessment (SHAPE) is a phase III randomized trial (ClinicalTrials.gov identifier: NCT01658930 ) reporting noninferiority of simple compared with radical hysterectomy for oncologic outcomes in low-risk cervical cancer. This study presents secondary outcomes of sexual health and quality of life (QOL) of the SHAPE trial. METHODS: Participants were randomly assigned to receive either radical or simple hysterectomy. Sexual health was assessed up to 36 months postoperatively using the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised and QOL using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Cervical Cancer-Specific Module (QLQ-CX24) questionnaires. RESULTS: Among participants with at least one QOL measure, clinical and pathologic characteristics were balanced and with no differences in preoperative baseline scores for sexual health or QOL between groups. FSFI total score met the cutoff for dysfunction up to 6 months ( P = .02) in the radical hysterectomy group. Group differences favored simple hysterectomy for FSFI subscales: desire and arousal at 3 months ( P ≤ .001) and pain and lubrication up to 12 months ( P ≤ .018). Both groups met the cutoff for sexual distress but was higher in radical hysterectomy at 3 months ( P = .018). For QLQ-CX24, symptom experience was significantly better up to 24 months ( P = .031) and body image better at 3, 24, and 36 months ( P ≤ .01) for simple hysterectomy. Sexual-vaginal functioning was significantly better up to 24 months ( P ≤ .022) and more sexual activity up to 36 months ( P = .024) in the simple hysterectomy arm. Global health status was significantly higher at 36 months for simple hysterectomy ( P = .025). CONCLUSION: Simple hysterectomy was associated with lower rates of sexual dysfunction than radical hysterectomy, with a lower proportion of women having sustained sexual-vaginal dysfunction. These results further support the benefit of surgical de-escalation for low-risk cervical cancer.
- 10 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (2) , 167-179
Top Cited PapersOpen AccessSexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
PURPOSE: Simple hysterectomy and pelvic node assessment (SHAPE) is a phase III randomized trial (ClinicalTrials.gov identifier: NCT01658930 ) reporting noninferiority of simple compared with radical hysterectomy for oncologic outcomes in low-risk cervical cancer. This study presents secondary outcomes of sexual health and quality of life (QOL) of the SHAPE trial. METHODS: Participants were randomly assigned to receive either radical or simple hysterectomy. Sexual health was assessed up to 36 months postoperatively using the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised and QOL using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Cervical Cancer-Specific Module (QLQ-CX24) questionnaires. RESULTS: Among participants with at least one QOL measure, clinical and pathologic characteristics were balanced and with no differences in preoperative baseline scores for sexual health or QOL between groups. FSFI total score met the cutoff for dysfunction up to 6 months ( P = .02) in the radical hysterectomy group. Group differences favored simple hysterectomy for FSFI subscales: desire and arousal at 3 months ( P ≤ .001) and pain and lubrication up to 12 months ( P ≤ .018). Both groups met the cutoff for sexual distress but was higher in radical hysterectomy at 3 months ( P = .018). For QLQ-CX24, symptom experience was significantly better up to 24 months ( P = .031) and body image better at 3, 24, and 36 months ( P ≤ .01) for simple hysterectomy. Sexual-vaginal functioning was significantly better up to 24 months ( P ≤ .022) and more sexual activity up to 36 months ( P = .024) in the simple hysterectomy arm. Global health status was significantly higher at 36 months for simple hysterectomy ( P = .025). CONCLUSION: Simple hysterectomy was associated with lower rates of sexual dysfunction than radical hysterectomy, with a lower proportion of women having sustained sexual-vaginal dysfunction. These results further support the benefit of surgical de-escalation for low-risk cervical cancer.
- 30 September 2022
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 82 (10) , e113
Werden Frauen zum Thema: urogynäkologische Spätfolgen nach vaginaler Geburt, von ihren Frauenärzt*innen aufgeklärt? Eine österreichische Umfrage
Zielsetzung Die möglichen Einschränkungen des Beckenbodens durch die vaginale Geburt ist ein sensibles, aber anderseits immer wichtiger werdendes Thema. Vor allem im Kontext des steigenden mütterlichen Alters bei der ersten Geburt und dem Wunsch nach Selbstbestimmung und Autonomie (z.B. Geburtsmodus), sind urogynäkologische Spätfolgen nach einer vaginalen Geburt ein präsentes Thema geworden. Materialien und Methoden Wir haben eine anonyme, Online-Umfrage in Österreich zum Thema: Aufklärung bzgl. urogynäkologischer Spätfolgen nach vaginaler Geburt durchgeführt. Die Umfrage erfolgte im Jahr 2021 mit SurveyMonkey über die OEGGG. Die teilnehmenden Frauenärzt*innen hatten 2 Monate Zeit, Mai/Juni, zu antworten. Ergebnisse Insgesamt haben 141 Frauenärzt*innen an der Umfrage teilgenommen, davon 88 (62%) Frauen und 53 (38%) Männer. Die höchste Rücklaufquote fand sich in der Gruppe zwischen 51 und 60 Jahren mit 36%. Mehr als die Hälfte, 81 (59%) der Frauenärzt*innen, gaben an, dass sie ihre Patientinnen über mögliche urogynäkologische Spätfolgen aufklären würden, wobei 26 (19%) angaben, das Thema aktiv anzusprechen und 96 (71%) „bei Bedarf“ darüber zu sprechen.61% der Frauenärzt*innen würden einen Kaiserschnitt als Alternative zur vaginalen Geburt anbieten, meistens auf Grund möglicher urogynäkologischer Spätfolgen und bei entsprechenden Risiken. 22 (16%) sprachen sich gegen das Anbieten des Kaiserschnittes aus. Zusammenfassung Unsere Umfrage legt nahe, dass nur wenige der Frauenärzt*innen in Österreich (etwa 19 %), mit ihren Patientinnen aktiv mögliche urogynäkologische Spätfolgen der Geburt besprechen. Es stellt sich die Frage, wie wir als Frauenärzt*innen mit diesem Thema zukünftig umgehen wollen und wie es sich auf die Sectiorate generell auswirken könnte. Article published online: 11 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 30 September 2022
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 82 (10) , e113
Werden Frauen zum Thema: urogynäkologische Spätfolgen nach vaginaler Geburt, von ihren Frauenärzt*innen aufgeklärt? Eine österreichische Umfrage
Zielsetzung Die möglichen Einschränkungen des Beckenbodens durch die vaginale Geburt ist ein sensibles, aber anderseits immer wichtiger werdendes Thema. Vor allem im Kontext des steigenden mütterlichen Alters bei der ersten Geburt und dem Wunsch nach Selbstbestimmung und Autonomie (z.B. Geburtsmodus), sind urogynäkologische Spätfolgen nach einer vaginalen Geburt ein präsentes Thema geworden. Materialien und Methoden Wir haben eine anonyme, Online-Umfrage in Österreich zum Thema: Aufklärung bzgl. urogynäkologischer Spätfolgen nach vaginaler Geburt durchgeführt. Die Umfrage erfolgte im Jahr 2021 mit SurveyMonkey über die OEGGG. Die teilnehmenden Frauenärzt*innen hatten 2 Monate Zeit, Mai/Juni, zu antworten. Ergebnisse Insgesamt haben 141 Frauenärzt*innen an der Umfrage teilgenommen, davon 88 (62%) Frauen und 53 (38%) Männer. Die höchste Rücklaufquote fand sich in der Gruppe zwischen 51 und 60 Jahren mit 36%. Mehr als die Hälfte, 81 (59%) der Frauenärzt*innen, gaben an, dass sie ihre Patientinnen über mögliche urogynäkologische Spätfolgen aufklären würden, wobei 26 (19%) angaben, das Thema aktiv anzusprechen und 96 (71%) „bei Bedarf“ darüber zu sprechen.61% der Frauenärzt*innen würden einen Kaiserschnitt als Alternative zur vaginalen Geburt anbieten, meistens auf Grund möglicher urogynäkologischer Spätfolgen und bei entsprechenden Risiken. 22 (16%) sprachen sich gegen das Anbieten des Kaiserschnittes aus. Zusammenfassung Unsere Umfrage legt nahe, dass nur wenige der Frauenärzt*innen in Österreich (etwa 19 %), mit ihren Patientinnen aktiv mögliche urogynäkologische Spätfolgen der Geburt besprechen. Es stellt sich die Frage, wie wir als Frauenärzt*innen mit diesem Thema zukünftig umgehen wollen und wie es sich auf die Sectiorate generell auswirken könnte. Article published online: 11 October 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 19 May 2022
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 82 (06) , S43-S44
Interdisziplinäres Vorgehen bei tief infiltrierender Darmendometriose: OP-Techniken und deren Outcome
Fragestellung Endometriose zählt zu den häufigsten gutartigen Erkrankungen in der Frauenheilkunde. Man nimmt an, dass zwischen 10 und 15% der Frauen im gebärfähigen Alter davon betroffen sind[1]. Die tief infiltrierende Endometriose des Darmes ist eine Form der Erkrankung, die durch infiltrierendes Wachstum die Organfunktionen des Rektums oder anderer Darmabschnitte massiv einschränken und typischerweise Beschwerden und Schmerzen beim Stuhlgang, besonders perimenstruell, verursachen kann. Nach präoperativem Assessment mittels Sonographie und Magnetresonanztomographie unter Anwendung der #ENZIAN Klassifikation erfolgte die interdisziplinäre Therapieplanung folgender operativer Therapiestrategien: Wir analysierten die an unserer Abteilung im Jahr 2021 bei tief infiltrierender Darmendometriose angewandten operativen Therapiestrategien hinsichtlich intra- bzw. postoperativer Komplikationen. Methodik Patientinnen mit tief infiltrierender Darmendometriose wurden nach Unterzeichnung einer Einverständniserklärung in diese Auswertung einbezogen. Die Planung & Durchführung der Endometriose-Operation erfolgte unabhängig von der Studienteilnahme an der Universitätsfrauenklinik Graz interdisziplinär zusammen mit den Universitätskliniken für Chirurgie, Urologie und Radiologie in strukturierten Fallbesprechungen. Von den Patientinnen wurden vor und nach der Operation sowie innerhalb der ersten 4 Wochen nach der Operation krankheits- und operationsrelevante Daten in einen DESS-Evaluationsbogen (Deep endometriosis surgical sheet) erhoben. Ergebnisse Zwischen Jänner 2021 und Dezember 2021 wurden insgesamt 13 Frauen aufgrund einer Darmendometriose per Laparoskopie an der Universitätsfrauenklinik Graz operiert. Alle Patientinnen hatten Schmerzsyndrome im Zusammenhang mit der Darmentleerung und in 54% war auch Infertilität die Indikation für die operative Sanierung. Außerdem klagten 44% der Patientinnen zusätzlich über schwere analgetikapflichtige Dysmenorrhoe und 24% über tiefe Dyspareunie. In 8% erfolgte nach individueller Therapieplanung eine Disk-Exzision des Endometrioseherdes, in 25% ein Shaving und in 67% der Fälle wurde eine Segmentresektion (Rektum, rektosigmoidaler Übergang bzw. Sigma) durchgeführt. Intraoperativ zeigten sich in den dokumentierten Fällen keine Komplikationen. Postoperativ kam es bei einer Patientin nach Segmentresektion des Rektums zu einer Ureterstriktur, die mittels passagerer Schienung erfolgreich behandelt werden konnte (Komplikation nach der Clavien Dindo Klassifikation Grad IIIb). Die erste Darmentleerung erfolgte durchschnittlich bereits nach 3,1 Tagen. Alle Patientinnen gaben an, 4 Wochen nach der Operation keine relevanten Darmentleerungsstörungen zu haben. Schlussfolgerungen Intra- und postoperativ konnten, mit Ausnahme von einer Ureterstriktur bei einer Patientin, keine Komplikationen beobachtet werden, insbesondere kam es in keinem Fall zu einer Anostomoseninsuffizienz. Mit diesen Ergebnissen können wir zeigen, dass durch ein interdisziplinäres und Befund-adaptiertes Vorgehen eine sichere Strategie verfolgt und mit geringer Morbidität sehr zufriedenstellende Ergebnisse erzielt werden können. Article published online: 10 June 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 19 May 2022
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 82 (06) , S43-S44
Interdisziplinäres Vorgehen bei tief infiltrierender Darmendometriose: OP-Techniken und deren Outcome
Fragestellung Endometriose zählt zu den häufigsten gutartigen Erkrankungen in der Frauenheilkunde. Man nimmt an, dass zwischen 10 und 15% der Frauen im gebärfähigen Alter davon betroffen sind[1]. Die tief infiltrierende Endometriose des Darmes ist eine Form der Erkrankung, die durch infiltrierendes Wachstum die Organfunktionen des Rektums oder anderer Darmabschnitte massiv einschränken und typischerweise Beschwerden und Schmerzen beim Stuhlgang, besonders perimenstruell, verursachen kann. Nach präoperativem Assessment mittels Sonographie und Magnetresonanztomographie unter Anwendung der #ENZIAN Klassifikation erfolgte die interdisziplinäre Therapieplanung folgender operativer Therapiestrategien: Wir analysierten die an unserer Abteilung im Jahr 2021 bei tief infiltrierender Darmendometriose angewandten operativen Therapiestrategien hinsichtlich intra- bzw. postoperativer Komplikationen. Methodik Patientinnen mit tief infiltrierender Darmendometriose wurden nach Unterzeichnung einer Einverständniserklärung in diese Auswertung einbezogen. Die Planung & Durchführung der Endometriose-Operation erfolgte unabhängig von der Studienteilnahme an der Universitätsfrauenklinik Graz interdisziplinär zusammen mit den Universitätskliniken für Chirurgie, Urologie und Radiologie in strukturierten Fallbesprechungen. Von den Patientinnen wurden vor und nach der Operation sowie innerhalb der ersten 4 Wochen nach der Operation krankheits- und operationsrelevante Daten in einen DESS-Evaluationsbogen (Deep endometriosis surgical sheet) erhoben. Ergebnisse Zwischen Jänner 2021 und Dezember 2021 wurden insgesamt 13 Frauen aufgrund einer Darmendometriose per Laparoskopie an der Universitätsfrauenklinik Graz operiert. Alle Patientinnen hatten Schmerzsyndrome im Zusammenhang mit der Darmentleerung und in 54% war auch Infertilität die Indikation für die operative Sanierung. Außerdem klagten 44% der Patientinnen zusätzlich über schwere analgetikapflichtige Dysmenorrhoe und 24% über tiefe Dyspareunie. In 8% erfolgte nach individueller Therapieplanung eine Disk-Exzision des Endometrioseherdes, in 25% ein Shaving und in 67% der Fälle wurde eine Segmentresektion (Rektum, rektosigmoidaler Übergang bzw. Sigma) durchgeführt. Intraoperativ zeigten sich in den dokumentierten Fällen keine Komplikationen. Postoperativ kam es bei einer Patientin nach Segmentresektion des Rektums zu einer Ureterstriktur, die mittels passagerer Schienung erfolgreich behandelt werden konnte (Komplikation nach der Clavien Dindo Klassifikation Grad IIIb). Die erste Darmentleerung erfolgte durchschnittlich bereits nach 3,1 Tagen. Alle Patientinnen gaben an, 4 Wochen nach der Operation keine relevanten Darmentleerungsstörungen zu haben. Schlussfolgerungen Intra- und postoperativ konnten, mit Ausnahme von einer Ureterstriktur bei einer Patientin, keine Komplikationen beobachtet werden, insbesondere kam es in keinem Fall zu einer Anostomoseninsuffizienz. Mit diesen Ergebnissen können wir zeigen, dass durch ein interdisziplinäres und Befund-adaptiertes Vorgehen eine sichere Strategie verfolgt und mit geringer Morbidität sehr zufriedenstellende Ergebnisse erzielt werden können. Article published online: 10 June 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 6 December 2021
- Published by Springer Nature in International Urogynecology Journal
- Vol. 33 (9) , 2357-2366
Preemptive local analgesia at vaginal hysterectomy: a systematic review
Introduction and hypothesis: We conducted a systematic review of the effectiveness of local preemptive analgesia for postoperative pain control in women undergoing vaginal hysterectomy. Methods: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews were searched systematically to identify eligible studies published through September 25, 2019. Only randomized controlled trials and systematic reviews addressing local preemptive analgesia compared to placebo at vaginal hysterectomy were considered. Data were extracted by two independent reviewers. Results were compared, and disagreement was resolved by discussion. Forty-seven studies met inclusion criteria for full-text review. Four RCTs, including a total of 197 patients, and two SRs were included in the review. Results: Preemptive local analgesia reduced postoperative pain scores up to 6 h and postoperative opioid requirements in the first 24 h after surgery. Conclusion: Preemptive local analgesia at vaginal hysterectomy results in less postoperative pain and less postoperative opioid consumption.
- 6 December 2021
- Published by Springer Nature in International Urogynecology Journal
- Vol. 33 (9) , 2357-2366
Open AccessPreemptive local analgesia at vaginal hysterectomy: a systematic review
Introduction and hypothesis: We conducted a systematic review of the effectiveness of local preemptive analgesia for postoperative pain control in women undergoing vaginal hysterectomy. Methods: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews were searched systematically to identify eligible studies published through September 25, 2019. Only randomized controlled trials and systematic reviews addressing local preemptive analgesia compared to placebo at vaginal hysterectomy were considered. Data were extracted by two independent reviewers. Results were compared, and disagreement was resolved by discussion. Forty-seven studies met inclusion criteria for full-text review. Four RCTs, including a total of 197 patients, and two SRs were included in the review. Results: Preemptive local analgesia reduced postoperative pain scores up to 6 h and postoperative opioid requirements in the first 24 h after surgery. Conclusion: Preemptive local analgesia at vaginal hysterectomy results in less postoperative pain and less postoperative opioid consumption.
- Top Cited PapersOpen Access
- 10 November 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (32) , 3623-3632
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL ( P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
- 10 November 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (32) , 3623-3632
Top Cited PapersOpen AccessRadiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL ( P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
- 17 May 2021
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 24 (1) , 108-112
Voiding dysfunction after colpectomy and urethral lengthening in transgender men
Colpectomy is a frequent part of gender-affirming surgery in transgender men. Urologic complications with these procedures can complicate and delay further management. Aim: We reviewed the rate of ...
- 17 May 2021
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 24 (1) , 108-112
Voiding dysfunction after colpectomy and urethral lengthening in transgender men
Colpectomy is a frequent part of gender-affirming surgery in transgender men. Urologic complications with these procedures can complicate and delay further management. Aim: We reviewed the rate of ...
- 1 September 2020
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 75 (9) , 549-550
Prophylactic Salpingectomy for Prevention of Ovarian Cancer at the Time of Elective Laparoscopic Cholecystectomy
(Abstracted from BJS 2020;107:519–524) The majority of ovarian cancers are now believed to originate in the fimbriae of the fallopian tubes as serous tubal intraepithelial carcinomas (STICs). Removal of the fallopian tubes (salpingectomy) has been associated with a reduced risk of developing ovarian cancer, leading to gynecologic societies recommending prophylactic salpingectomy at the time of pelvic surgery in appropriate women.
- 1 September 2020
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 75 (9) , 549-550
Prophylactic Salpingectomy for Prevention of Ovarian Cancer at the Time of Elective Laparoscopic Cholecystectomy
(Abstracted from BJS 2020;107:519–524) The majority of ovarian cancers are now believed to originate in the fimbriae of the fallopian tubes as serous tubal intraepithelial carcinomas (STICs). Removal of the fallopian tubes (salpingectomy) has been associated with a reduced risk of developing ovarian cancer, leading to gynecologic societies recommending prophylactic salpingectomy at the time of pelvic surgery in appropriate women.